Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


iCAD VeraLook cleared

This article was originally published in The Gray Sheet

Executive Summary

Computer-aided detection system for computed tomography colonography has gained 510(k) clearance from FDA, iCAD reports Aug. 4. VeraLook can automatically identify polyps and streamline the image reading process, the firm said, noting a typical exam may contain 1,200-1,500 images per patient. Last year, CMS issued a national non-coverage decision for CT colonography, also known as virtual colonoscopy, for colorectal cancer screening (1"The Gray Sheet" May 18, 2009). iCAD also markets the SecondLook mammography CAD system

You may also be interested in...

Medicare Denies Coverage Of CT Colonography For Cancer Screening

The hopes of imaging equipment and software makers, the American Cancer Society and radiologists were dashed with CMS' final decision not to cover computed tomography colonography for colorectal cancer screening

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts